Clinical trial

89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer

NCT03065764

Study summary

ClinicalTrials.gov

89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention 89Zr-Pembrolizumab Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2017-01-20

PhasePHASE2

Conditions

Non Small Cell Lung Cancerunresolved

Interventions

89Zr-PembrolizumabDRUG

Sponsors & collaborators

Amsterdam UMC, location VUmclead sponsor

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

AmsterdamNorth Holland, Netherlands1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03065764 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.